File name:2019-3-3-1 How AI and Biomarkers Will Drive Progress in Longevity Science
Published:2019-11-24 18:11:59
Update:2020-05-18 16:15:47
How AI and Biomarkers Will Drive Progress in
Longevity Science

Dmitry Kaminskiy, Margaretta Colangelo
Aging is the single biggest risk factor for developing many diseases including Alzheimer's, Parkinson's,
cancer, osteoporosis, and cardiovascular disease. Few breakthroughs would make as profound an impact on
humanity as delaying aging. Curing aging would have a greater impact on society than curing cancer.
Longevity Science is driven by the convergence of multiple distinct technological and biomedical sectors and
sub-sectors including geroscience, geriatrics, regenerative medicine, precision medicine, digital health, and
advanced technologies. Longevity scientists seek to end the threat of age-related disease for this and future
generations by developing a comprehensive understanding of the biology of aging itself. Science is showing
that chronological aging is inevitable but biological aging is malleable. AI and biomarkers will accelerate
real-world implementations of Longevity Science leading to a paradigm shift from Precision Medicine to
Precision Health. AI and biomarkers will be the central factors driving progress of Longevity Science. In the
short term, deep diagnostic and prognostic technologies enabled by AI will empower people to maintain an
optimal state of health until the final stages of life. In the long term, the most promising areas of Longevity
Science are those that intervene at the root causes of aging to delay the onset of age-related disease. (Am J
Transl Med 2019. 3:96-103).
Copyright(C)2017 American Journal of Translational Medicine